Alluvi, formerly BI 4744, represents a significant development in obesity treatment. This dual activator targeting both glucagon-like peptide-1 and GIP receptors demonstrates remarkable efficacy in research https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/